GSK plc 6-K, filed Jun 14, 2021
GSK plc (GSK)
6-K
2021-06-14
For: 2021-06-14
View Original
Added on
April 10, 2026
About this 6-K
GSK plc filed this 6-K on June 14, 2021.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of June 2021
Commission
File Number 001-15170
GlaxoSmithKline plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ____
14 June 2021, London UK & Gosselies Belgium
GSK and iTeos Therapeutics announce development and
commercialisation collaboration for EOS-448, an anti-TIGIT
monoclonal antibody, enabling novel next-generation immuno-oncology
combinations
●
EOS-448 is currently in phase I for advanced solid tumours with a
randomised PD-1 combination study planned for 2022
●
iTeos to receive a $625 million upfront payment in addition to
potential milestones, and royalty payments on ex-US
sales
●
GSK and iTeos will co-commercialise and share profits in the
US
●
GSK now has the
leading portfolio of
antibodies targeting the CD226 axis - a key target for
next-generation immuno-oncology therapies
Dr Hal Barron, Chief Scientific Officer and President R&D, GSK,
said: "Immuno-oncology has
transformed cancer care but unfortunately less than 30 percent of
patients respond to treatment with the current leading immune
checkpoint inhibitors. Based on the underlying science, we believe
that combinations of a PD-1, TIGIT, CD96 and PVRIG inhibitor could
become transformative medicines for many patients with cancer. We
are excited to collaborate with the team at iTeos and together we
can play a leading role in the next generation of immuno-oncology
therapies."
Since GSK validated the role of CD226 axis targets as important in
oncology, it has been strategically building a carefully
constructed set of assets to target this network of checkpoint
inhibitors. The addition of EOS-448 results in GSK being the only
company with antibodies targeting all three known checkpoints -
TIGIT (via EOS-448), CD96 (via GSK'608), and PVRIG (via GSK'562).
Together with GSK's recently approved anti-PD-1, Jemperli
(dostarlimab), this comprehensive portfolio of potential next
generation immuno-oncology agents will be explored through various
novel combinations, including doublets and triplets, to evaluate
their potential to transform treatment options for patients with
multiple different cancers.
Michel Detheux, President and CEO, iTeos, said: "Through this transformative collaboration,
iTeos now has access to GSK's best-in-class resources which will
provide us with a significant advantage in a highly competitive,
global market. We have chosen GSK because of their commercial
capabilities, experience in immuno-oncology and their commitment to
invest in the rapid advancement of our TIGIT programme and create a
clear path forward for EOS-448. Inspired by the multifaceted
mechanism of action of EOS-448 and promising early results in
clinical trials, this collaboration allows us to accelerate and
expand the clinical development of EOS-448. We are more confident
than ever in our ability to succeed. This collaboration validates
our science and provides a catalyst for the future of iTeos. The
collaboration with GSK will allow our team to continue to develop
next generation immunotherapies starting with inupadenant, our
highly differentiated clinical-stage A2A adenosine receptor
antagonist, and to drive scientific innovation with our expertise
in tumour immunology to build our pipeline."
EOS-448 is currently in an open-label phase I study in patients
with advanced solid tumours. GSK and iTeos plan to start
combination studies of EOS-448 with dostarlimab in 2022. GSK'608
(anti-CD96 being developed in collaboration with 23andMe) is in
phase I as monotherapy and in combination with dostarlimab. GSK
expects to submit an Investigational New Drug application for
GSK'562 (anti-PVRIG in-licensed as SRF-813 from Surface Oncology)
by mid-2022.
Under the terms of the collaboration agreement, iTeos will receive
an upfront payment of $625 million. iTeos will be eligible to
receive up to an additional $1.45 billion in milestone payments,
should the EOS-448 programme achieve certain development and
commercial milestones.
Within the collaboration, GSK and iTeos will share responsibility
and costs for the global development of EOS-448 and will jointly
commercialise and equally split profits in the US. Outside of the
US, GSK will receive an exclusive license for commercialisation and
iTeos will receive tiered royalty payments.
The collaboration agreement is conditional upon customary
conditions including review by the appropriate regulatory agencies
under the Hart-Scott-Rodino Act.
###
Conference Call Details
iTeos will host a conference call to discuss the agreement today,
Monday, June 14 at 8:30 a.m. ET. Details are as
follows:
Participant Dial-In: (833) 607-1661
International Dial-In: (914) 987-7874
Conference ID: 4598012
Webcast: https://edge.media-server.com/mmc/p/xz7hasbz
The live audio webcast will also be accessible from the Events page
of the Company's IR website at https://investors.iteostherapeutics.com/news-and-events/events.
A replay will be available on the Company's website approximately
two hours after completion of the event and for 30 days following
the call.
###
GSK in Oncology
GSK is focused on maximising patient survival through
transformational medicines. GSK's pipeline is focused on
immuno-oncology, cell therapy, cancer epigenetics and synthetic
lethality. Our goal is to achieve a sustainable flow of new
treatments based on a diversified portfolio of investigational
medicines utilising modalities such as small molecules, antibodies,
antibody drug conjugates and cells, either alone or in
combination.
About GSK
GSK is a science-led global healthcare company. For further
information please visit www.gsk.com/about-us.
About EOS-448
EOS-448 is a monoclonal human IgG1 antibody designed to bind with
high affinity TIGIT, a negative co-stimulatory immune checkpoint
expressed T cells and NK cells. EOS-448 potently triggers an
antitumor response by the immune system via a multi-faceted
mechanism. By binding to TIGIT, EOS-448 blocks its interaction
with TIGIT ligands including CD155 and CD112, which can then bind
to CD226 and activate immune response of T cells and NK cells.
In addition, IgG1 binds
to FccR to
trigger pro-inflammatory
cytokine release, activation of antigen presenting cells and
depletion of TIGIT+ Tregs and exhausted T cells. In a phase 1 dose
escalation, presented at AACR 2021, EOS-448 showed a favorable
tolerability profile and early signs of clinical activity in
advanced cancers with one confirmed partial response and 9 stable
diseases out of 20 evaluable patients with advanced, difficult to
treat cancers. Depletion of TIGIT+ suppressive and exhausted cells
were shown at even the lowest tested dose thereby providing
evidence of engagement of the FccR, and the potential of EOS-448 to
activate multiple immune mechanisms. This program was funded by a
SPW/EER grant.
About iTeos Therapeutics, Inc.
iTeos Therapeutics is a clinical-stage biopharmaceutical company
pioneering the discovery and development of a new generation of
highly differentiated immuno-oncology therapeutics for patients.
The Company's innovative pipeline includes two clinical-stage
programs targeting novel, validated immuno-oncology. The initial
antibody product candidate, EOS-448, is a high affinity, potent,
anti-TIGIT antibody with a functional Fc domain, designed to
enhance the anti-tumor response through a multifaceted immune
modulatory mechanism. An open-label Phase 1 clinical trial of
EOS-448 is ongoing in adult cancer patients with advanced solid
tumors with preliminary data indicating preliminary clinical
activity as a monotherapy and a favorable tolerability profile. The
Company is also advancing inupadenant, a first insurmountable
adenosine A2A receptor antagonist in clinical development tailored
to overcome cancer immunosuppression. iTeos is conducting an
open-label multi-arm Phase 1/2a clinical trial of inupadenant in
adult cancer patients with advanced solid tumors. Preliminary
results indicate encouraging single-agent activity as well as the
identification of a potential predictive biomarker. iTeos
Therapeutics is headquartered in Cambridge, MA with a research
center in Gosselies, Belgium.
iTeos Therapeutics, Inc. Forward-Looking Statements
This press release contains forward-looking statements and
information within the meaning of The Private Securities Litigation
Reform Act of 1995 and other federal securities laws. Any
statements contained in this press release that are not statements
of historical fact may be deemed to be forward-looking statements.
Words such as "believes," "anticipates," "plans," "expects,"
"will," "intends," "potential," "possible" and similar expressions
are intended to identify forward-looking statements. These
forward-looking statements include but are not limited to
statements regarding the closing of the transaction; iTeos'
right to receive any upfront payment, milestones and royalty
payments from GSK pursuant to the agreement and GSK's obligation to
share responsibility and costs for the global development of
EOS-448; EOS-448's potential as a promising target for the next
generation of immuno-oncology therapies; the potential of
combinations of TIGIT, CD96 and PVRIG to become transformative
medicines for many patients with cancer; GSK's best-in-class
resources providing iTeos with a significant advantage in
a highly competitive global market; the potential of the
collaboration with GSK to accelerate and expand the clinical
development of EOS-448; iTeos' plan to continue to develop
next generation immunotherapies starting with inupadenant; and GSK
and iTeos' plan to start combination studies of EOS-448
with dostarlimab in 2022.
These forward-looking statements involve risks and uncertainties
that may cause actual results to differ materially from those
expressed or implied in the forward-looking statements. Many
of these risks and uncertainties are beyond iTeos' control.
Known risk factors include, among others, market conditions, the
expected benefits and opportunities related to the agreement
between iTeos and GSK may not be realized or may take
longer to realize than expected due to a variety of reasons,
including any inability of the parties to perform their commitments
and obligations under the agreement, challenges and uncertainties
inherent in product research and development and manufacturing
limitations; success in preclinical testing and early clinical
trials does not ensure that later clinical trials will be
successful, and early results from a clinical trial do not
necessarily predict final results; the data for EOS-448 may not be
sufficient for obtaining regulatory approval; iTeos may
not be able to execute on its business plans, including meeting its
expected or planned regulatory milestones and timelines, research
and clinical development plans, and bringing its product candidates
to market, for various reasons, some of which may be outside
of iTeos' control, including possible limitations of company
financial and other resources, manufacturing limitations that may
not be anticipated or resolved for in a timely manner, regulatory,
court or agency decisions such as decisions by the United States
Patent and Trademark Office with respect to patents that cover our
product candidates and the impact of the COVID-19 pandemic; and
those risks identified under the heading "Risk Factors"
in iTeos's most recent Annual Report on Form 10-K for the
year ended December 31, 2020 and most recent Quarterly Report on
Form 10-Q filed with the Securities and Exchange Commission (SEC)
as well as other SEC filings made by the Company which you are
encouraged to review.
Any of the foregoing risks could materially and adversely affect
the Company's business, results of operations and the trading price
of iTeos' common stock. We caution investors not to place
considerable reliance on the forward-looking statements contained
in this press release. iTeos does not undertake any
obligation to publicly update its forward-looking statements based
on events or circumstances after the date
hereof.
|
GSK enquiries:
|
|
|
|
|
Media
enquiries:
|
Simon
Steel
|
+44 (0)
20 8047 5502
|
(London)
|
|
|
Tim
Foley
|
+44 (0)
20 8047 5502
|
(London)
|
|
|
Kristen
Neese
|
+1 804
217 8147
|
(Philadelphia)
|
|
|
Kathleen
Quinn
|
+1 202
603 5003
|
(Washington
DC)
|
|
|
|
|
|
|
|
|
|
|
|
Analyst/Investor
enquiries:
|
James
Dodwell
|
+44 (0)
20 8047 2406
|
(London)
|
|
|
Sonya
Ghobrial
|
+44 (0)
7392 784784
|
(Consumer)
|
|
|
Mick
Readey
|
+44 (0)
7990 339653
|
(London)
|
|
|
Jeff
McLaughlin
|
+1 215
751 7002
|
(Philadelphia)
|
|
|
Frannie
DeFranco
|
+1 215
751 4855
|
(Philadelphia)
|
iTeos enquiries:
Media contact: media@iteostherapeutics.com
Investor contact: Ryan Baker; Ryan.Baker@iteostherapeutics.com
Cautionary statement regarding forward-looking
statements
GSK
cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such factors
include, but are not limited to, those described in the Company's
Annual Report on Form 20-F for 2020 and any impacts of the COVID-19
pandemic.
Registered in England & Wales:
No.
3888792
Registered Office:
980
Great West Road
Brentford,
Middlesex
TW8
9GS
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GlaxoSmithKline plc
|
|
|
(Registrant)
|
|
|
|
|
Date: June
14, 2021
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GlaxoSmithKline plc
|